Recurrent Primary Peritoneal Carcinoma Completed Phase 2 Trials for Dasatinib (DB01254)

IndicationStatusPhase
DBCOND0031168 (Recurrent Primary Peritoneal Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00671788A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaTreatment